Neuropsychiatric Lupus Erythematosus
Autor: | Antonella Afeltra, G. Coppolino, Roberto Massa, Amelia Rigon, Francesca Buzzulini, A. Palma Modoni, M. Vadacca |
---|---|
Rok vydání: | 2011 |
Předmět: |
lcsh:Internal medicine
Pediatrics medicine.medical_specialty Psychosis Magnetic Resonance Spectroscopy lcsh:Medicine Disease Sensitivity and Specificity Diagnosis Differential Rheumatology Neuroimaging Prevalence Humans Medicine Medical History Taking lcsh:RC31-1245 Cyclophosphamide Lupus erythematosus business.industry Mechanism (biology) Lupus Vasculitis Central Nervous System lcsh:R Plasmapheresis medicine.disease Magnetic Resonance Imaging Thrombosis Methotrexate Anti-Anxiety Agents Antirheumatic Agents Immunology Antibodies Antiphospholipid Tomography X-Ray Computed business Vasculitis Neurocognitive Immunosuppressive Agents Antipsychotic Agents |
Zdroj: | Europe PubMed Central Reumatismo, Vol 58, Iss 3, Pp 177-186 (2011) |
ISSN: | 2240-2683 0048-7449 |
DOI: | 10.4081/reumatismo.2006.177 |
Popis: | Neuropsychiatric involvement in patients with Systemic Lupus Erythematosus (SLE), first mentioned by Kaposi more than 100 years ago, still remains one of the main challenge facing rheumatologist and other physicians. The diagnosis of neuropsychiatric SLE (NPSLE) is complex not only because of the considerable prevalence variation (14-80%) but also because of the wide spectrum of NP manifestations. They vary from overt neurologic alterations (seizure, psychosis), to subtle abnormalities (neurocognitive dysfunctions). Different NP manifestations result from a variety of mechanisms including antibodies, vasculitis, thrombosis, hemorrhages and cytokine-mediated damages. Of note, despite the dramatic clinical manifestations, too often changes at the morphological neuroimaging techniques are minimal and non specific. There is no one diagnostic tool specific for NPSLE and diagnosis must be based on the combinated use of immunoserological tests, functional and anatomical neuroimaging and standardized specific criteria. Symptomatic, immunosuppressive and anticoagulant therapies are the main strategies available in the management of these patients. Therapy for CNS lupus should be adjusted according to the needs of the individual patients. The coming years promise to be an important time for the development of new neuroimaging techniques and for the study of disease mechanism. An early and objective identification of brain involvement will allow for appropriate treatment to avoid severe complications. |
Databáze: | OpenAIRE |
Externí odkaz: |